Unresectable or Metastatic Melanoma

Unresectable or metastatic melanoma - Patient guide

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Click here for Prescribing Information on Tafinlar

Click here for Prescribing Information on Mekinist

A patient guide to treatment of unresectable or metastatic melanoma

This guide and the Tafinlar and Mekinist Patient Diary are designed to help your patients work with their healthcare team throughout their treatment for unresectable or metastatic melanoma.

It includes valuable information such as:

What is melanoma?
What are Tafinlar and Mekinist?
How to take Tafinlar and Mekinist
How to store Tafinlar and Mekinist
Contraceptive and fertility information
Possible drug interactions
What to expect
Possible side effects
A treatment diary

Download PDF Order

Rate this content:

November 2024 | IE11251848

Oncology

Print

×

Ask Speakers

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.